Akums Drugs and Pharmaceuticals Ltd, the New Delhi-based contract development and manufacturing organisation, has entered into a long-term agreement with an undisclosed global pharma firm for manufacturing and supply of formulations in the European market.
The agreement is in line with Akums’ growth plans to expand in Europe and other regulated markets, alongside local manufacturing.
As per the deal, estimated at Euro 200-mn (Rs. 1,760-crore), Akums will produce and supply multiple stock keeping units of oral liquid formulations, which the partner company will market across various European countries, as per a stock market announcement by the company.
The commercial supply of these products is expected to begin in 2027 and will continue to be supplied till 2032, the company said. As part of this initiative, Akums will initiate the European approval process for its oral liquid manufacturing facility, leveraging this approval to produce the contracted products. “The site and product dossier approvals are expected to be received by the end of 2026,” Akums said, adding that it already operates two European-approved facilities for injectables and oral solids.
As part of the deal, Akums will receive an upfront payment of Euro 100-mn (Rs. 880-crore) for product development and site approval from European authorities.
Commenting on the development, Akums’ Managing Director Mr. Sanjeev Jain said, “This opens doors for us to further expand our footprints in regulated markets and replicate the domestic CDMO success globally.”
Mr. Sandeep Jain, Managing Director of Akums added, “These products are currently being manufactured in Europe. Manufacturing these products in India opens further collaboration opportunities with other global pharma companies to optimise their manufacturing costs and make their supply chain robust”.


31 December, 2024 16:45:46 IST 
















